Merck Serono, a division of Merck KGaA, has entered into an agreement that broadens the scope of the collaboration with Newron Pharmaceuticals S.p.A. The two companies are already collaborating on the development of safinamide in Parkinson’s disease. Newron will receive a development license for two Merck clinical-stage compounds, pruvanserin and sarizotan. Merck will retain buy-back options for each compound upon completion of proof-of-concept trials. Should these options be exercised by Mer...